Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $2.90, $0.04 better than the analyst estimate of $2.86. Revenue for the quarter came in at $667.5 million versus the consensus estimate of $681.29 million.

Full-Year 2025 Financial Outlook

Bio-Rad is providing its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue growth of approximately 1.5 to 3.5 percent and an estimated non-GAAP operating margin of approximately 13.0 to 13.5 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.